On August 11, 2014, Aegerion Pharmaceuticals, Inc. (the "Company") entered into
a Purchase Agreement (the "Purchase Agreement") with Jefferies LLC and J.P.
Morgan Securities LLC (the "Representatives"), as the representatives of the
initial purchasers (the "Initial Purchasers") relating to the sale of $300
million aggregate principal amount of 2.00% Convertible Senior Notes due 2019
(the "Notes") to the Initial Purchasers. The Company also granted the Initial
Purchasers options to purchase up to an additional $45.0 million aggregate
principal amount of the Notes.

The Purchase Agreement includes customary representations, warranties and
covenants. Under the terms of the Purchase Agreement, the Company has agreed to
indemnify the Initial Purchasers against certain liabilities.

The foregoing description of the Purchase Agreement does not purport to be
complete and is qualified in its entirety by reference to the Purchase
Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and
is incorporated herein by reference.

Convertible Bond Hedge and Warrant Transactions

In connection with the offering of the Notes, on August 11, 2014, the Company
entered into convertible bond hedge transactions with two counterparties,
Jefferies International Limited and JPMorgan Chase Bank, National Association,
London Branch (the "Option Counterparties"). The convertible bond hedge
transactions are generally expected, but not guaranteed, to reduce the potential
dilution and/or offset the cash payments the Company is required to make in
excess of the principal amount of converted Notes, in each case, upon conversion
of the Notes in the event that the market price per share of the Company's
common stock, as measured under the terms of the convertible bond hedge
transactions, is greater than the conversion price of the Notes. The Company
also entered into warrant transactions in which it sold warrants to the Option
Counterparties exercisable into a maximum of 14,571,960 shares of its common
stock, which are subject to customary anti-dilution adjustments. The strike
price of the warrants will initially be $53.375 per share, which is 75% above
the last reported sale price of the Company's common stock on August 11,
2014. The warrants are exercisable over the 100 trading day period beginning on
November 15, 2019. The warrant transactions could have a dilutive effect to the
extent that the market price per share of the Company's common stock exceeds the
applicable strike price of the warrants during the measurement period at the
maturity of the warrants. The Company paid the Option Counterparties
approximately $80.0 million for the convertible bond hedge transactions and
received approximately $55.9 million from the Option Counterparties for the
warrants, resulting in a net cost to the Company of approximately $24.1 million.
The Company may enter into one or more additional convertible bond hedge
transactions and warrant transactions if the Initial Purchasers exercise their
options to purchase up to an additional $45.0 million aggregate principal amount
of the Notes.

Aside from the initial payment of a premium to the Option Counterparties, the
Company will not be required to make any cash payments to the Option
Counterparties under the convertible bond hedge transactions and will be
entitled to receive from the Option Counterparties a number of shares of the
Company's common stock, an amount of cash or a combination of cash and shares of
the Company's common stock generally based on the amount by which the market
price per share of the Company's common stock, as measured under the terms of
the convertible bond hedge transactions, is greater than the conversion price of
the Notes during the relevant valuation period under the convertible bond hedge
transactions. However, if the market price per share of the Company's common
stock, as measured under the terms of the warrant transactions, exceeds the
strike price of the warrants during the measurement period at the maturity of
the warrants, the Company will owe the Option Counterparties shares of its
common stock. The Company will not receive any additional proceeds if warrants
are exercised.

The foregoing description of the convertible bond hedge transactions and warrant
transactions is qualified in its entirety by reference to the base convertible
bond hedge transaction confirmations relating to the convertible bond hedge
transactions and the base warrant transaction confirmations relating to the
warrant transactions with each of the two Option Counterparties, which are filed
as Exhibits 10.1 through 10.4 to this Current Report on Form 8-K and are
incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities

As described in Item 1.01 of this Current Report on Form 8-K, which is
incorporated herein by reference, on August 11, 2014, the Company entered into
warrant transactions with each of the Option Counterparties. Pursuant to the
warrant transactions, the Company issued 7,285,980 warrants with a strike price
of $53.375 per share. The number of warrants and the strike price are subject to
adjustment under certain circumstances described in the warrant transaction
confirmations. The Company offered and sold the warrants in reliance on the
exemption from registration provided by Section 4(a)(2) of the Securities Act.
Neither the warrants nor the underlying shares of common stock (issuable in the
event the market price per share of the common stock exceeds the strike price of
the warrants on the date the warrants are exercised) have been registered under
the Securities Act. Neither the warrants nor such underlying shares of common
stock may be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.

Item 8.01 Other Events

On August 11, 2014, the Company issued a press release announcing the Company's
proposed private offering of the Notes pursuant to Rule 144A under the
Securities Act of 1933, as amended. A copy of the press release is filed as
Exhibit 99.1 hereto and is incorporated by reference.

On August 12, 2014, the Company issued a press release announcing the pricing of
the Notes. A copy of the press release is filed as Exhibit 99.2 hereto and is
incorporated by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

1.1 Purchase Agreement, dated as of August 11, 2014, between Aegerion
Pharmaceuticals, Inc. and Jefferies LLC and J.P. Morgan Securities LLC, as
Representatives of the Initial Purchasers
10.1 Base convertible bond hedge transaction confirmation, dated as of August
11, 2014, by and between Jefferies International Limited and Aegerion
Pharmaceuticals, Inc., in reference to the 2.00% Convertible Senior Notes
due 2019
10.2 Base convertible bond hedge transaction confirmation, dated as of August
11, 2014, by and between JPMorgan Chase Bank, National Association, London
Branch and Aegerion Pharmaceuticals, Inc., in reference to the 2.00%
Convertible Senior Notes due 2019
10.3 Base issuer warrant transaction confirmation, dated as of August 11, 2014,
by and Jefferies International Limited and Aegerion Pharmaceuticals, Inc.,
in reference to the 2.00% Convertible Senior Notes due 2019
10.4 Base issuer warrant transaction confirmation, dated as of August 11, 2014,
by and between JPMorgan Chase Bank, National Association, London Branch
and Aegerion Pharmaceuticals, Inc., in reference to 2.00% Convertible
Senior Notes due 2019
99.1 Press Release dated August 11, 2014
99.2 Press Release dated August 12, 2014